In 2023, Biovault worked alongside 6 NHS trusts to process 1,552 cellular therapy products and to release 753, making us a leading provider of PBSC services.
Quality & Safety, Regulatory Partnerships, Cellular Therapies, Innovation, Ethical Practices
Donor lymphocyte infusions (DLI) and clinical readiness. Discover Biovault’s pre-prepared DLI processing and storage approach for faster access and reduced risk.
Industry Events, Company News, Cellular Therapies
5 key takeaways from EBMT 2026, from expanded cord blood and JACIE quality to regulation, infrastructure and the future of cell therapy.
Cellular Therapies, Innovation
Explore how PBSCs enabled CAR-T and immune effector cell therapies, and how Biovault supports safe processing, storage and delivery of advanced cellular medicines.
Cellular Therapies
How peripheral blood stem cells became the preferred source for transplantation, and how Biovault supports PBSC collection pathways through compliant processing and storage.
